Drug Index


Mechanism :

It is an atypical anti-psychotic. However, unlike the other atypical antipsychotics, it is a partial agonist at dopamine D2 and serotonin type 1 (5-HT1A) receptors. It is also an antagonist at serotonin type 2 (5-HT2A) receptor and has alpha-blocking activity. It also acts as a partial agonist at the 5-HT2C receptor with high affinity. and this may underlie the minimal weight gain seen in the course of therapy.

Indication :

  • Bipolar disorder
  • Schizophrenia
  • Autism
  • Tourette syndrome

Contraindications :

Hypersensitivity to the aripiprazole or its components.

Dosing :

Schizophrenia and Mania:
13-17 years: 2 mg/day orally for 2 days; increase gradually to reach the recommended dose of 10 mg/day. Maximum dose: 30 mg/day.
Autism and Tourette syndrome:
6-17 years: 5-10 mg/day. Start with 2 mg/day and increase gradually to the recommended dose. Maximum dose: 15 mg/day.
Discontinue if absolute neutrophil count (ANC) falls <1000/cumm.

Adverse Effect :

Headache, agitation, insomnia, anxiety, dizziness, light headedness, somnolence, tremors, extrapyramidal signs, blurred vision, neuroleptic malignant syndrome, seizure, tardive dyskinesia, altered mental status, autonomic instability, nausea, vomiting, constipation, dry mouth/xerostomia, dysphagia, orthostatic hypotension, stiffness, myalgia, rash, weight gain, fatigue, restlessness, hyperpyrexia.

Interaction :

Carbamazepine: Can markedly decrease the amount of aripiprazole in the body by increasing the rate at which the body's enzymes (particularly the liver enzyme, CYP3A4) degrade it. The dose of aripiprazole should therefore be doubled when used with carbamazepine. Other drugs that can promote the activity of CYP3A4 and decrease the body's levels of aripiprazole are phenytoin, rifampin and phenobarbital.
Ketoconazole: Can increase the amount of aripiprazole in the body by blocking CYP3A4. Aripiprazole’s dose should be reduced by one-half during ketoconazole therapy. Many other drugs also are known to block CYP3A4 and potentially could increase the levels of aripiprazole. These drugs include: itraconazole, fluconazole, voriconazole, cimetidine, verapamil, diltiazem, erythromycin, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir and grapefruit juice.
Quinidine: Inhibits another liver enzyme known as CYP2D6 that also breaks down aripiprazole and can increase the amount of aripiprazole in the body. It is recommended to reduce the dose of aripiprazole by one-half during quinidine therapy. Other medicines that block CYP2D6 include fluoxetine and paroxetine.
Alpha-1 receptor blockers [Doxazosin, Prazosin, Terazosin], used for control of blood pressure and prostatic enlargement: May increase the chance of hypotension.

Renal Dose :

Dose in Renal Impairment GFR (mL/min)
20-50Dose as in normal renal function
10-20Dose as in normal renal function
<10Dose as in normal renal function

Dose in Patients undergoing Renal Replacement Therapies
CAPDNot dialysed. Dose as in normal renal function
HDNot dialysed. Dose as in normal renal function
HDF/High fluxUnlikely to be dialysed. Dose as in normal renal function
CAV/VVHDNot dialysed. Dose as in normal renal function

Hepatic Dose :

No dosage adjustments are recommended.
03/24/2024 12:31:19 Aripiprazole
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0